Kira Pharma
Dr. Richard Lee comes to the Kira team after serving as Head of Hematology at Alexion Pharmaceuticals, a global company specializing in rare diseases. He has served in clinical and medical affairs leadership roles at pharmaceutical and biotechnology companies including Bayer, Roche, Genentech, Millennium/Takeda, and Bristol-Myers-Squibb, gaining significant experience developing products across a large spectrum of small molecules, proteasome inhibitors, and large biologics. He has been crucial in the development and launch of first-to-market medicines throughout his career.
He completed his MD from Indiana University School of Medicine, MBA from George Washington University and his Bachelor of Science degree in Chemistry from the University of Arizona.
Kira Pharma
Kira Pharmaceuticals is a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases. Enabled by its proprietary LOGIC drug discovery platform, Kira is committed to advancing first-in-class and best-in-class therapies to patients around the world. The company is headquartered in Cambridge, Massachusetts with an R&D center in Suzhou, China.